Lenalidomide vs TQB3820

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Lenalidomide

Marketed by Bristol-Myers Squibb and partners

Approved in Multiple Myelomasmall molecule (IMiD / cereblon modulator)
Reliable signal

NCT00056160 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 353 patients with previously treated multiple myeloma and used a hard clinical primary endpoint, time to tumor progression. The primary comparison was met: median TTP was 60.1 weeks (95% CI 41.1–80.0) with lenalidomide plus dexamethasone versus 20.1 weeks (95% CI 16.1–21.1) with placebo plus dexamethasone, a large, clearly favorable separation. The trial's strong design and positive primary result make this high-quality evidence for lenalidomide.

Next expected readout: November 2026 · NCT06505369 (registry estimate)

Reported efficacy

Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months); Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008) (From randomization up to cut-off date of 02 March 2008; up to 51 months): Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7) (met)

Result source: NCT00424047

TQB3820

Developed by Sino Biopharmaceutical

small molecule
Weak signal

NCT05020639 · Phase 1 · status unknown

This is a single-arm, open-label, non-randomized dose-escalation study designed to determine a tolerable dose rather than to test clinical benefit, with no comparator arm and no blinding. Results have not yet been posted. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLenalidomideTQB3820
PFS, median35.3 vs 21.8+13.5 vs placebon 351NCT01850524
13 other results
—Not reported
OS, median39.3 vs 31.5+7.8 vs placebon 177NCT00056160
8 other results
—Not reported
ORR78.5% vs 65.5%vs Lenalidomide + Dexamethasonen 321NCT01239797
12 other results
  • 82.5% 20/56 mg/m^2 once weekly · n 228 · Phase 3 · primary NCT03859427
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 82% vs 80% n 351 · Phase 3 · secondary NCT01850524
  • 92.9% vs 76.4% n 281 · Phase 3 · secondary NCT02076009
  • 92.9% vs 81.6% n 368 · Phase 3 · secondary NCT02252172
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 75.1% vs 62.3% n 535 · Phase 3 · secondary NCT00689936
  • 73.4% vs 62.3% n 541 · Phase 3 · secondary NCT00689936
  • 80.7% vs 67.5% n 535 · Phase 3 · secondary NCT00689936
  • 78.6% vs 67.5% n 541 · Phase 3 · secondary NCT00689936
  • 91.7% vs 75% n 48 · Phase 3 · secondary NCT02252172
  • 62.5% n 24 · Phase 3 · secondary NCT00928486
—Not reported
VGPR or better75.8% vs 44.2%vs Lenalidomide, Low-dose Dexamethasonen 281NCT02076009
1 other result
  • 81.5% vs 56.9% n 368 · Phase 3 · secondary NCT02252172
—Not reported
MRD negativity53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
  • 60.9% vs 39.4% n 197 · Phase 3 · primary NCT03652064
  • 59% vs 50% wk 72 · n 335 · Phase 3 · secondary NCT01850524
  • 32.1% vs 11.1% n 368 · Phase 3 · secondary NCT02252172
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
—Not reported

PFS, median

Lenalidomide
35.3 vs 21.8+13.5 vs placebon 351NCT01850524
13 other results
TQB3820
—Not reported

OS, median

Lenalidomide
39.3 vs 31.5+7.8 vs placebon 177NCT00056160
8 other results
TQB3820
—Not reported

ORR

Lenalidomide
78.5% vs 65.5%vs Lenalidomide + Dexamethasonen 321NCT01239797
12 other results
  • 82.5% 20/56 mg/m^2 once weekly · n 228 · Phase 3 · primary NCT03859427
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 82% vs 80% n 351 · Phase 3 · secondary NCT01850524
  • 92.9% vs 76.4% n 281 · Phase 3 · secondary NCT02076009
  • 92.9% vs 81.6% n 368 · Phase 3 · secondary NCT02252172
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 75.1% vs 62.3% n 535 · Phase 3 · secondary NCT00689936
  • 73.4% vs 62.3% n 541 · Phase 3 · secondary NCT00689936
  • 80.7% vs 67.5% n 535 · Phase 3 · secondary NCT00689936
  • 78.6% vs 67.5% n 541 · Phase 3 · secondary NCT00689936
  • 91.7% vs 75% n 48 · Phase 3 · secondary NCT02252172
  • 62.5% n 24 · Phase 3 · secondary NCT00928486
TQB3820
—Not reported

VGPR or better

Lenalidomide
75.8% vs 44.2%vs Lenalidomide, Low-dose Dexamethasonen 281NCT02076009
1 other result
  • 81.5% vs 56.9% n 368 · Phase 3 · secondary NCT02252172
TQB3820
—Not reported

MRD negativity

Lenalidomide
53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
  • 60.9% vs 39.4% n 197 · Phase 3 · primary NCT03652064
  • 59% vs 50% wk 72 · n 335 · Phase 3 · secondary NCT01850524
  • 32.1% vs 11.1% n 368 · Phase 3 · secondary NCT02252172
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
TQB3820
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TQB3820: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lenalidomide: 4 of 4 rows · TQB3820: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenalidomide
Dropout rate
63.8%a
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 33 more results
—
NCT00424047 · Phase 3 · combination
n/a: no completion milestone
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
16.2%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
49.3%Ixazomib + LenDex
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.8%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.6%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02322320 · Phase 3 · registry result, not featured evidence
0%
NCT01109004 · Phase 3 · registry result, not featured evidence
1%
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Lenalidomide and Dexamethasone (Rd
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide and Dexamethasone Rd1
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide and Low-Dose Dexameth
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneMPR+R
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneMPR+p
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01621672 · Phase 3 · registry result, not featured evidence
—Lenalidomide ( ExtensionPhase) 22
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide (Treatment Phase) Up
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide and Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide+Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
40%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
51.3%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00179647 · Phase 3 · registry result, not featured evidence
0%
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
6.1%
NCT03477539 · Phase 2 · registry result, not featured evidence
5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
19.8%a
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 33 more results
—
NCT00424047 · Phase 3 · combination
—
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
—20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—Ixazomib + LenDex
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
—
NCT02322320 · Phase 3 · registry result, not featured evidence
—
NCT01109004 · Phase 3 · registry result, not featured evidence
—
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Lenalidomide and Dexamethasone (Rd
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
13.1%Lenalidomide and Dexamethasone Rd1
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
12.7%Lenalidomide and Low-Dose Dexameth
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
20.4%MPR+R
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
17.6%MPR+p
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
—
NCT01621672 · Phase 3 · registry result, not featured evidence
—Lenalidomide ( ExtensionPhase) 22
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide (Treatment Phase) Up
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide and Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
—Lenalidomide+Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
8%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
18.2%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
19.3%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
15.4%
NCT00179647 · Phase 3 · registry result, not featured evidence
—
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
—
NCT03477539 · Phase 2 · registry result, not featured evidence
—
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
62.7%a
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 33 more results
59.7%
NCT00424047 · Phase 3 · combination
72.1%
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
72.4%
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
79.4%
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
37.7%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
32.5%20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—Ixazomib + LenDex
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
65.4%Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
73%Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
79%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
74.8%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
6.7%
NCT02322320 · Phase 3 · registry result, not featured evidence
20.6%
NCT01109004 · Phase 3 · registry result, not featured evidence
65.3%
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
57%Lenalidomide and Dexamethasone (Rd
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
—Lenalidomide and Dexamethasone Rd1
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
71.1%Lenalidomide and Low-Dose Dexameth
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
44%MPR+R
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
40.8%MPR+p
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
72%
NCT01621672 · Phase 3 · registry result, not featured evidence
23.8%Lenalidomide ( ExtensionPhase) 22
NCT00622336 · Phase 3 · registry result, not featured evidence
53.6%Lenalidomide (Treatment Phase) Up
NCT00622336 · Phase 3 · registry result, not featured evidence
42.7%Lenalidomide and Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
—Lenalidomide+Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
48%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
57.9%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
54.9%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
45.9%
NCT00179647 · Phase 3 · registry result, not featured evidence
39.1%
NCT02969837 · Phase 2 · registry result, not featured evidence
13.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
26.5%
NCT03477539 · Phase 2 · registry result, not featured evidence
22.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
fatigue 64.4% (placebo 60%)
neutropenia 49.2% (placebo 6.9%)
diarrhoea 48% (placebo 30.3%)
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 27 more results
constipation 40.3% (placebo 23.4%)
neutropenia 40.3% (placebo 9.7%)
diarrhoea nos 38.1% (placebo 25.7%)
NCT00424047 · Phase 3 · combination
diarrhoea 56.3%
peripheral sensory neuropathy 55.8%
neutropenia 54.8%
NCT03652064 · Phase 3 · registry result, not featured evidence
neutropenia 65.4%
diarrhoea 59.7%
upper respiratory tract infection 43.5%
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 65.1%
neutropenia 61.5%
fatigue 44.8%
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
20/56 mg/m^2 once weekly
neutropenia 29.1%
anaemia 25.1%
hypertension 21.5%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
20/27 mg/m^2 twice weekly
neutropenia 31.6%
hypertension 24.2%
anaemia 23.8%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 77% (placebo 30%)
oedema peripheral 55.5% (placebo 32.5%)
constipation 48.2% (placebo 38.1%)
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 41.7% (placebo 30%)
oedema peripheral 40.5% (placebo 32.5%)
constipation 36.2% (placebo 38.1%)
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 51.8%
fatigue 49.3%
oedema peripheral 43.9%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 50%
fatigue 48.4%
anaemia 42.5%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 43.4%
anaemia 42.3%
neutropenia 40.1%
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
constipation 38.9%
diarrhoea 38%
anaemia 35.4%
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 46.6%
anaemia 44.5%
constipation 43.8%
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
neutropenia 78%
thrombocytopenia 68.7%
anaemia 66%
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
neutropenia 76.3%
thrombocytopenia 65.8%
anaemia 59.9%
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
grade 1 hypoalbuminemia 68%
grade 1 thrombocytopenia 52%
grade 2 leukopenia 36%
NCT01621672 · Phase 3 · registry result, not featured evidence
asthenia 14.3%
headache 14.3%
anaemia nos 9.5%
NCT00622336 · Phase 3 · registry result, not featured evidence
anaemia nos 0%
asthenia 0%
headache 0%
NCT00622336 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 77.1%
hemoglobin 64.6%
glucose, serum-high (hyperglycemia) 55.2%
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
neutropenia 80%
lymphopenia 64%
leukopenia 60%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
fatigue 42.4%
neutropenia 41.4%
muscle spasms 34.4%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
muscle spasms 24.3%
fatigue 22.9%
leukopenia 19.4%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
fatigue 56%
neutropenia 32.3%
muscle cramp 25.6%
NCT00179647 · Phase 3 · registry result, not featured evidence
fatigue 63%
diarrhea 45.7%
edema limbs 37%
NCT02969837 · Phase 2 · registry result, not featured evidence
lymphocyte decreased 36.7%
lymphocyte decreased 33.3%
wbc decreased 33.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
platelet count decreased 93.9%
anemia 91.8%
neutrophil count decreased 83.7%
NCT03477539 · Phase 2 · registry result, not featured evidence
lymphocyte count decreased 85%
neutrophil count decreased 77.5%
white blood cell decreased 72.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 26 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenalidomide

Time to Progression 13.87 vs 4.64 placebo months
time to event · months
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 60.1 weeks as posted
show 7 more results
12.02 vs 4.64 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 52.1 weeks as posted
12.09 vs 4.64 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 52.4 weeks as posted
NA vs 18.43 Lenalidomide, Low-dose Dexamethasone months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs 40.87 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
45.8 vs 26.8 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
34.18 vs 14.15 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 148.1 weeks as posted
14.47 vs 14.15 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 62.7 weeks as posted
Overall Survival 39.25 vs 31.48 placebo months
time to event · months
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 170.1 weeks as posted
show 12 more results
NA vs NA placebo months
NCT00424047 · Phase 3 · combination
37.36 vs 30.76 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 161.9 weeks as posted
67.58 vs 51.84 Lenalidomide, Low-dose Dexamethasone months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
90.25 vs 64.07 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
NA vs NA placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
60.42 vs 57.56 Ld months
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
48.3 vs 39.62 Lenalidomide + Dexamethasone months
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
48.3 vs 40.4 Lenalidomide and Dexamethasone (Rd) months
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
59.1 vs 49.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
62.3 vs 49.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
NA vs NA MPp+p months
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
NA vs NA MPp+p months
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
ORR 60.5% (n=177) vs 19.3% (n=176) placebo
event count · % of participants
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to % from 107 Participants as posted
Duration of Response 15.6 vs 7.68 placebo months
time to event · months
NCT00424047 · Phase 3 · combination · converted to months from 67.6 weeks as posted
show 11 more results
15.72 vs 7.68 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 68.1 weeks as posted
NA vs 17.4 Lenalidomide, Low-dose Dexamethasone months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs 43.7 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
50.6 vs 37.5 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) months
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
35 vs 22.3 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
22.1 vs 22.3 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
31.5 vs 22.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
21.5 vs 22.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
28.06 vs 12.78 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 121.6 weeks as posted
12.95 vs 12.78 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 56.1 weeks as posted
Time to ECOG Worsening 2.33 vs 2.84 placebo months
time to event · months
NCT00424047 · Phase 3 · combination · converted to months from 10.1 weeks as posted
show 1 more result
2.33 vs 2.84 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 10.1 weeks as posted
MRD Negative 53.3% (n=197) vs 35.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
responder rate · % of participants
NCT03652064 · Phase 3 · registry result, not featured evidence
show 3 more results
60.9% (n=197) vs 39.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
NCT03652064 · Phase 3 · registry result, not featured evidence
32.1% (n=368) vs 11.1% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
59% (n=335) vs 50% (n=347) placebo @ 72wk
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
PFS NA vs 18.43 Lenalidomide, Low-dose Dexamethasone months
time to event · months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 13 more results
NA vs 31.87 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
45.3 vs 29.6 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
35.3 vs 21.8 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
31.38 vs 29.47 Ld months
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
19.35 vs 14.85 Lenalidomide + Dexamethasone months
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
19.42 vs 14.92 Lenalidomide + Dexamethasone months
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
26.3 vs 17.6 Lenalidomide and Dexamethasone (Rd) months
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
25.5 vs 21.2 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
20.7 vs 21.2 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
26 vs 21.9 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
21 vs 21.9 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
31.41 vs 12.95 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 136.1 weeks as posted
14.33 vs 12.95 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 62.1 weeks as posted
VGPR or Better 75.8% (n=281) vs 44.2% (n=276) Lenalidomide, Low-dose Dexamethasone
responder rate · % of participants
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 1 more result
81.5% (n=368) vs 56.9% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
ORR 92.9% (n=281) vs 76.4% (n=276) Lenalidomide, Low-dose Dexamethasone
responder rate · % of participants
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 9 more results
92.9% (n=368) vs 81.6% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
91.7% (n=48) vs 75% (n=44) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
82% (n=351) vs 80% (n=354) placebo
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
78.5% (n=321) vs 65.5% (n=325) Lenalidomide + Dexamethasone
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
87.1% (n=396) vs 66.7% (n=396) Lenalidomide and Dexamethasone (Rd)
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
75.1% (n=535) vs 62.3% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
73.4% (n=541) vs 62.3% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
80.7% (n=535) vs 67.5% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
78.6% (n=541) vs 67.5% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
Time to Response 1 vs 1.3 Lenalidomide, Low-dose Dexamethasone months
time to event · months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 7 more results
1.02 vs 1.87 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
2.31 vs 3.74 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 10 weeks as posted
2.15 vs 3.74 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 9.3 weeks as posted
CR/sCR 51.1% (n=368) vs 30.1% (n=369) Lenalidomide + Dexamethasone
responder rate · % of participants
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Stringent Complete 35.6% (n=368) vs 15.7% (n=369) Lenalidomide + Dexamethasone
responder rate · % of participants
NCT02252172 · Phase 3 · registry result, not featured evidence · combination

+ 128 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenalidomide's landscape · TQB3820's landscape